Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...

GSK signed an exclusive licence deal with Hansoh Pharma in 2023, laying out up to $1.71bn in an upfront payment plus ...

The combination of tarlatamab and standard anti-PD-L1 therapy as first-line maintenance therapy led to “unprecedented” survival gains among patients with extensive-stage small cell lung cancer ...

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

Transcription factors, especially FOXP1, are crucial in SCLC chemoresistance, influencing drug sensitivity and resistance pathways. FOXP1 regulates SP8 expression via its super-enhancer, impacting the ...

Mona Bratter had trouble breathing after surgery in 2023 to treat her small-cell lung cancer (SCLC). But when her oncologist suggested palliative care to help manage her discomfort, she was hesitant. ...

Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a ...

Small cell lung cancer (SCLC) is an aggressive form of lung cancer that has a short doubling time. The term “doubling time” refers to the amount of time it takes for a cell or tumor to double in size.

Small cell lung cancer (SCLC) often spreads to the brain, where it tends to be very aggressive. Although median survival is about 6 months, with advances in treatment, experts think life expectancy ...